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ORIGINAL ARTICLE

Transferrin lipoplex-mediated suicide gene therapy of oral
squamous cell carcinoma in an immunocompetent murine model
and mechanisms involved in the antitumoral response
S Neves1, H Faneca1, S Bertin2,3, K Konopka4, N Düzgünes¸4, V Pierrefite-Carle2,3,
S Simões1,5 and MC Pedroso de Lima1,6
1

Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal; 2INSERM, Unite´ 638,
Nice, France; 3Faculte´ de Me´decine, Universite´ de Nice Sophia Antipolis, Nice, France; 4Department of
Microbiology, University of the Pacific, Arthur A. Dugoni School of Dentistry, San Francisco, CA, USA;
5
Laboratory of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
and 6Department of Biochemistry, Faculty of Science and Technology, University of Coimbra, Coimbra,
Portugal
Suicide gene therapy has been used for the treatment of a variety of cancers. We reported previously the in vitro efficacy of the
Herpes Simplex Virus Thymidine kinase (HSV-tk)/ganciclovir (GCV) system to mediate cytotoxicity in oral squamous cancer cells,
using transferrin (Tf)-lipoplexes, prepared from cationic liposomes composed of 1,2-dioleoyl-3-(trimethylammonium) propane
(DOTAP) and cholesterol. In the present study, we evaluated the antitumoral efficacy mediated by this lipoplex formulation in two
suicide gene therapy strategies, HSV-tk/GCV and cytosine deaminase (CD)/5-fluorocytosine (5-FC), using a syngeneic, orthotopic
murine model for head and neck squamous cell carcinoma. The cellular and molecular events associated with the antitumoral
response elicited by both the therapeutic approaches were investigated by analyzing tumor cell death, tumor-infiltrating immune
cells and tumor cytokine microenvironment. Significant tumor reduction was achieved upon intratumoral delivery of HSV-tk or CD
genes mediated by Tf-lipoplexes, followed by intraperitoneal injection of GCV or 5-FC, respectively. Enhanced apoptosis, the
recruitment of NK cells, CD4 and CD8 T-lymphocytes and an increase in the levels of several cytokines/chemokines were observed
within the tumors. These observations suggest that suicide gene therapy with lipoplexes modifies the tumor microenvironment, and
leads to the recruitment of immune effector cells that can act as adjuvants in reducing the tumor size.
Cancer Gene Therapy (2009) 16, 91–101; doi:10.1038/cgt.2008.60; published online 8 August 2008
Keywords: suicide gene therapy; orthotopic murine model for HNSCC; Tf-lipoplexes; tumor cell apoptosis; activation of the
immune system

Introduction

Head and neck squamous cell carcinoma (HNSCC)
represents the sixth most common cancer in developed
countries.1 Despite recent advances in early detection and
diagnosis, current treatments of oral cancer are unsatisfactory and the 5-year survival rate has not improved
over the last two decades.2,3 Strategies for cancer gene
therapy include selective prodrug activation by ‘suicide’
genes, inhibition of activated oncogenes by antisense
oligonucleotides, ribozymes or siRNAs, inhibition of
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angiogenesis and transfer of tumor suppressor and
cytokine genes.4,5
The prodrug/suicide gene approach involves the delivery of a ‘suicide’ gene into cells, rendering them sensitive
to a specific prodrug.6 Among the different suicide gene
therapy strategies, the Herpes Simplex Virus thymidine
kinase (HSV-tk)/ganciclovir (GCV) and the bacterial
cytosine deaminase (CD)/5-fluorocytosine (5-FC) are
the most commonly used.7 The delivery of the HSV-tkexpressing plasmid to target cells results in the expression
of viral thymidine kinase, which selectively phosphorylates GCV. Monophosphorylated GCV is further phosphorylated by endogenous cellular kinases into an active
triphosphate purine analog compound. This product is
incorporated into cellular DNA, causing chain termination and cell death.8,9 On the other hand, the CD gene
encodes an enzyme which, when expressed in mammalian
cells, is capable of converting the non-toxic antifungal
agent 5-FC into the widely used chemotherapeutic drug
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5-fluorouracil. 5-FU is then processed to either 5-fluorouracil triphosphate, which is incorporated into RNA and
interferes with RNA processing, or 5-fluoro-2-deoxyuridine-5-monophosphate, which irreversibly inhibits thymidylate synthase and interferes with DNA synthesis.10
One of the major limitations of gene therapy is
the effective delivery of therapeutic genes into target
cells. Although viral vectors have proven to be highly
efficient in mediating gene expression, which resulted in
their use in the majority of clinical trials, safety concerns
with the use of viruses has dampened the enthusiasm
for their application in the clinic. Therefore, research
in gene therapy has been focused on the development
of suitable non-viral carriers. Among such non-viral
vectors, cationic liposome-DNA complexes (lipoplexes)
emerged as promising systems because of their low
toxicity and immunogenicity, lack of pathogenicity and
versatility.11,12 An increasing number of clinical trials
using cationic liposomes have been reported, illustrating
their potential as viable alternatives to viral vectors in
gene therapy.13
A significant disadvantage of cationic liposomes is
their low transfection efficiency as compared with viral
vectors.12,14,15 However, this drawback may be overcome
by using suicide gene therapy, because with such an
approach transfected tumor cells (effector cells) appear
to be capable of inducing death of neighboring nontransfected cells, a phenomenon called local bystander
effect. This effect was shown to result in extensive
cytotoxicity and complete tumor eradication.16 In this
regard, suicide gene therapy appears as a strategy of
choice for the use of non-viral vectors as the low gene
transfer efficiency can be compensated by the local
bystander effect. Moreover, the disadvantage of a
transient gene expression mediated by cationic liposomes
can be surpassed, because transgene long-term expression
is not absolutely required, as it can be relayed by immune
system activation.17
Aiming at a successful application of lipoplexes in
gene therapy, several strategies have been explored which
incorporate components from biological systems that
have naturally evolved the capacity to surpass certain
cellular barriers. These include association of targeting
ligands,18–20 fusogenic proteins21,22 or peptides23,24 and
NLS25,26 peptides. In this regard, we and others have
demonstrated that association of human transferrin to
cationic liposome/DNA complexes enhances transfection
in a large variety of cells, including dividing18,19,27 and
non-dividing cells.28–30
As demonstrated in our recent work,27 Tf-lipoplexes
containing 1,2-dioleoyl-3-(trimethylammonium) propane
(DOTAP)/cholesterol mediated the highest levels of
transfection in oral cancer cells in culture, HSC-3 and
SCC-7, when prepared at the 3/2 lipid/DNA (±) charge
ratio. We have also reported that delivery of HSV-tkexpressing plasmid to these cells mediated by Tflipoplexes followed by ganciclovir treatment resulted in
essentially 100% cytotoxicity. Cell death was shown to
occur mainly by an apoptotic process and the observed
cytotoxicity was attributed to the bystander effect
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taking place through diffusion of the toxic agent into
neighboring cells through gap junctions. Moreover, our
in vivo preliminary results indicated that Tf-lipoplexes
containing DOTAP/cholesterol, prepared at the 3/2
charge ratio, were advantageous over naked plasmid
DNA in reducing tumor growth upon intratumoral
administration of the HSV-tk-expressing plasmid
followed by intraperitoneal (i.p.) injection of ganciclovir
in a syngeneic orthotopic murine model for HNSCC.27
In the present study, we explored different transfection
conditions and further evaluated the potential of
this lipoplex formulation in the suicide gene therapy
approaches, HSV-tk/GCV and CD/5-FC, using the same
animal model. In addition, the cellular and molecular
events associated with the antitumoral response induced
by both the therapeutic approaches were investigated by
analyzing tumor cell death, tumor-infiltrating immune
cells and tumor cytokine microenvironment.
Materials and methods

Chemicals
The cationic lipid DOTAP, and cholesterol (Chol), were
purchased from Avanti Polar Lipids (Alabaster, AL,
USA). Iron-saturated human transferrin was obtained
from Sigma (St Louis, MO, USA). The plasmid pCMVtk
encodes the therapeutic gene thymidine kinase and was
obtained from the National Gene Vector Laboratory at
the University of Michigan (Ann Arbor, MI, USA). The
plasmid pCMVSPORT-LacZ (Gibco BRL, Gaithersburg,
MD, USA) encodes the reporter gene b-galactosidase
and was used to determine transfection efficiency. The
pCDbgeo plasmid encodes the therapeutic gene cytosine
deaminase gene under the control of the CMV promoter.31 Plasmids were produced using the Qiagen endo-free
plasmid giga kit (Qiagen, Hilden, Germany), according to
the manufacturer’s instructions. GCV was a gift from the
University Hospital of Coimbra. 5-FC was obtained from
Roche (Fontenay Sous Bois, France).
Cells and animal model
SCC-7 murine oral squamous cell carcinoma cells
(a gift of Dr B O’Malley and Dr D Li) were maintained
at 37 1C, under 5% CO2, in Dulbecco’s modified Eagle’s
medium-high glucose (DMEM-HG) (Sigma) supplemented with 10% (v v1) heat-inactivated fetal bovine serum
(FBS) (Sigma), penicillin (100 U ml1), streptomycin
(100 mg ml1) and sodium bicarbonate (1.6 g l1). For
generation of oral tumors, SCC-7 cells were trypsinized,
washed and resuspended in cold phosphate-buffered
saline (PBS) (0.14 mM NaCl, 2.7 mM KCl, 1.5 mM
KH2PO4, 8.1 mM Na2HPO4, pH 7.4), to obtain a cell
density of 2  106 cells ml1.
Experiments were performed using a syngeneic
orthotopic murine model for HNSCC developed by
O’Malley et al.32,33 All the surgical procedures and the
care given to the animals were in accordance with institutional guidelines. Six- to eight-week-old female C3H/
HeOuJ mice (Charles River Laboratories, Barcelona,
Spain) were anesthetized upon intramuscular injection of
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a mixture of chlorpromazine (2 mg kg1) and ketamine
(100 mg kg1). The tumor model was established by
injecting 1  105 SCC-7 cells in a volume of 50 ml directly
into the floor of the mouth, through the neck skin, using a
30 gauge needle.

Cationic liposomes and lipoplexes
Small unilamellar cationic liposomes were prepared by
extrusion of multilamellar liposomes (MLV) composed of
a 1:1 (mole ratio) mixture of DOTAP and cholesterol
(Chol). Briefly, lipids (Avanti Polar Lipids, Alabaster,
AL, USA) dissolved in CHCl3 were mixed at the desired
molar ratio and dried under vacuum in a rotatory
evaporator. The dried lipid film was hydrated with
deionized water to a final lipid concentration of 20 mM
and the resulting multilamellar liposomes were then
sonicated for 3 min, and extruded, 21 times, through
two stacked polycarbonate filters of 50 nm pore diameter
using a Liposofast device (Avestin, Toronto, Canada).
Transferrin-associated lipoplexes (Tf-lipoplexes) were
prepared by pre-incubating the liposomes (the amount
required for the 3/2 lipid/DNA (±) charge ratio) with
human transferrin (32 mg mg1 of DNA) (Sigma) for
15 min, followed by a further 15 min incubation with
plasmid DNA solution containing 40 mg of pCMVtk,
pCDbgeo or pCMV.SPORT-bgal, at room temperature.
Under these conditions, the added amount of plasmid
DNA (40 mg) is completely complexed with transferrinassociated liposomes.
Transfection efficiency
Transfection efficiency was evaluated by scoring the
percentage of tumor cells expressing b-galactosidase using
X-gal as a colorogenic substrate.19 For this purpose,
15 mm cryosections of tumors treated with PBS or
Tf-lipoplexes were fixed for 15 min with 4% (v v1)
paraformaldehyde in 4% sucrose and then washed two
times with PBS for 5 min and stained with a solution
containing X-gal (1 mg ml1). The samples were incubated
at 37 1C for 24 h and analyzed under a phase contrast
microscope (Leica DMIL, Leica Microsystems, Bannockburn, IL, USA) and photographed with a digital camera
(Canon Powershot S-40, Canon, Tokyo, Japan). Alternatively, b-galactosidase expression was evaluated by
immunohistochemical analysis. Six mm cryosections of
tumors were sequentially incubated with 1% Triton
(3  15 min), 10% FBS (30 min) and the monoclonal
anti-b-gal antibody (1:5000, Molecular Probes) (30 min)
at room temperature. Afterwards, slices were washed
with 1% Triton (3  15 min), incubated for 1 h with a
biotinylated secondary antibody (1:200, Amersham,
Uppsala, Sweden), washed with 1% Triton (3  15 min)
and then incubated for 1 h with the streptavidin–alkaline
phosphatase complex (1:200, Sigma). After washing three
times with TBS, and once with Tris-HCl, pH 9.5, the
histochemical localization of b-gal was visualized with
5-bromo-4-chloro-3-indolyl-phosphate (Sigma) (3.4 ml ml1
from a 50 mg ml1 stock solution in 100% dimethylformamide) and nitroblue tetrazolium (Sigma) (4.5 ng ml1 from
a 70 mg ml1 stock solution in 70% dimethylformamide),

in staining buffer (15.8 g l1 Tris-HCl, 5.84 g l1 NaCl,
10.16 g l1 MgCl2.6H2O, pH 9.5). Incubation was stopped
by washing the sections with deionized water, which were
subsequently dehydrated in graded ethanol and cleared
in toluene. The slices were then mounted with Entellan
(Merck) in cover slips and examined under a light
microscope (Leica) and photographed with a digital
camera (Canon).

Antitumoral activity
Five days after implantation of SCC-7 cells into the
floor of the six- to eight-week-old female C3H/HeOuJ
mice, the animals were anesthetized as described above,
and the developed tumors were injected with 40 mg
of plasmid DNA (pCMV.SPORT-Bgal, pCMVtk or
pCDbgeo) in 50 ml of PBS, either naked or complexed
with Tf-associated liposomes at a 3/2 (±) charge ratio
(182 nmol of cationic lipid). The same volume of PBS was
also injected into control animals. Four hours after,
mice were injected daily through i.p. administration with
GCV (50 mg kg1) or 5-FC (100 mg kg1) for the animals
treated with pCMVtk or pCDbgeo, respectively. The
mean tumor volume at the beginning of treatment was
around 36 mm3. Animals were observed daily with special
attention to tumor size, which was measured in three
dimensions with calipers.
TUNEL assay
DNA fragmentation as an index of apoptosis was
detected by terminal deoxynucleotidyl transferase (TdT)mediated dUTP nick end labeling (TUNEL) using a
DeadEnd Colorimetric TUNEL Assay kit (Promega),
according to the manufacturer’s instructions. Briefly,
8 days after administration of the different treatments,
animals were killed, tumors were removed. Six mm
cryosections of tumors were fixed for 15 min in 4%
(v v1) paraformaldehyde and then washed two times with
PBS for 5 min. Sections were incubated with proteinase K
(20 mg ml1) for 20 min at room temperature and further
washed two times in PBS. Slices were further incubated
for 10 min with equilibration buffer (200 mM potassium
cacodylate (pH 6.6), 25 mM Tris-HCl (pH 6.6), 0.2 mM
DTT, 0.25 mg ml1 bovine serum albumin, 2.5 mM CoCl2)
prior to incubation for 1 h at 37 1C in a humidified
chamber with dTdT reaction mixture prepared according
to the manufacturer’s instructions (biotinylated nucleotides, equilibration buffer and rTdT enzyme). The
reaction was stopped by immersing the slices into a saline
citrate solution (0.3 M NaCl, 0.67 M sodium citrate, pH
7.2). Endogenous peroxidases were blocked with 0.3%
H2O2 solution for 5 min before incubation with streptavidin horseradish peroxidase (HRP) for 30 min at
room temperature. For visualization, the sections were
treated with 0.05% diaminobenzidin solution containing
0.01% H2O2. Samples were mounted with Dako medium
(DAKO, Glostrup, Denmark) and TUNEL-positive
apoptotic nuclei were observed by light microscopy under
a Zeiss Axioscope microscope (Zeiss, Jena, Germany) and
identified by the presence of dark brown staining.
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Tumoral infiltration of T and NK cells
Six mm cryostat tumor sections were fixed with acetone,
blocked using 10% FBS and incubated for 1 h with an
FITC-labeled rat anti-mouse mAb against CD3 protein
(Pharmingen, BD Biosciences, San José, USA), PElabeled rat anti-mouse mAb against CD8 protein (Abd
serotec, Oxford, UK) and Alexa Fluors 647-labelled rat
anti-mouse mAb against CD94 protein (NK cells) (Abd
serotec). Unbound antibody was removed by washing
with PBS. Sections were then observed by fluorescence
microscopy using a Zeiss axioskop2 microscope and the
number of immunostained cells was counted under a
microscopic field at  400 magnification.
Detection of cytokines and chemokines in tumors
The presence of cytokines and chemokines in tumors was
detected by FlowCytomix (Bender Medsystems, Austria),
an ELISA-based flow cytometry assay, according to the
manufacturer’s instructions. Briefly, 8 days after administration of the different treatments, animals were killed,
tumors were removed and homogenized in lysis buffer
(50 mM Tris-HCl, pH 8.0; 150 mM NaCl, 2 mM EDTA;
0.1% Triton X-100; 2 mM DTT, 0.1 mM PMSF and
1 mg ml1 of a protease inhibitor cocktail (Sigma)). The
protein content of the lysates was measured by the Dc
Protein Assay reagent (Biorad, Hercules, CA, USA) using
bovine serum albumin as the standard and samples were
diluted to obtain a protein concentration of 1 mg ml1.
IL-10, IL-2, TNF-a, IFN-g and RANTES standard
solutions were prepared according to the manufacturer’s
instructions. The standard solutions and samples were
directly added to cytometry tubes and incubated for 2 h in
the dark at room temperature, with antibodies for each
molecule associated to beads or biotin. These mixtures
were then washed two times with assay buffer from the
FlowCytomix kit by centrifugation at 200 g for 5 min and
subsequently incubated, for 1 h in the dark at room
temperature, with streptavidin-PE and finally washed
two times with assay buffer from the FlowCytomix kit
by centrifugation at 200 g for 5 min. IL-10, IL-2, TNF-a,
IFN-g and RANTES expression levels in tumor tissue
were measured using a FACSCalibur System (Becton
Dickinson), according to the manufacturer’s instructions.
Data were expressed as cytokine/chemokine concentration in pg ml1.
Statistical analysis
Data were analyzed using the Prism software (version
4.0). Statistically significant differences (Po0.001) between the experimental groups were determined by
one-way analysis of variance (ANOVA) for cytokine
and chemokine detection experiments and by two-way
ANOVA for antitumoral activity experiments.

Results

In vivo transfection efficiency of Tf-lipoplexes
We have previously demonstrated the in vitro efficacy of
the HSV-tk/GCV suicide gene therapy in oral squamous
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cancer cells using Tf-lipoplexes, prepared from cationic
liposomes composed of DOTAP:Chol (1:1, mole ratio)
and associated with transferrin.27 We reported that transfection of human oral HSC-3 and murine oral SCC-7 cells
was optimal when Tf-lipoplexes were prepared at a 3/2
(±) lipid/DNA charge ratio. Therefore, this formulation
was selected for the present work. Before testing the
antitumoral effect of these strategies in this animal model,
we evaluated the efficiency of Tf-lipoplexes to mediate
in vivo transfection of SCC-7 cells. Figure 1 shows the
levels of b-galactosidase gene expression evaluated using
X-gal as a colorigenic substrate (a) or by immunohistochemistry (b). Tf-lipoplexes were able to transfect
SCC-7 cells in vivo when directly injected into tumors,
although at a relatively low extent (approximately 10%
transfection).

Antitumoral effect of HSV-tk/GCV suicide gene therapy
To investigate whether intratumoral delivery of the
HSV-tk gene mediated by Tf-lipoplexes would result in
tumor cell killing and size reduction upon GCV treatment, mice with an established tumor in the floor of the
mouth were submitted to different treatments. As illustrated in Figure 2a, injection of DOTAP/Chol-Tf-tk was
significantly more effective in delaying tumor progression
than PBS or naked pCMVtk injections. At day 7 after
treatment, a significant reduction in tumor size was
observed in pCMVtk-treated animals when gene delivery
was mediated by Tf-lipoplexes (Po0.001) as compared
with PBS-treated mice or mice that received naked
pCMVtk. However, a decrease in tumor size (Po0.05)
was also observed upon intratumoral administration
of DOTAP/Chol-Tf-b-gal or pCMVtk in the absence
of GCV treatment (data not shown), although much
less pronounced than that achieved upon injection of
DOTAP/Chol-Tf-tk followed by GCV treatment.
Aiming at improving the therapeutic response in terms
of tumor size reduction and ultimately its complete
eradication, we tested the effect of repeated intratumoral
administrations of Tf-lipoplexes containing 40 mg
pCMVtk followed by GCV treatment for 14 days after
the first gene delivery (Figure 2b). As observed, at day 14
after the first treatment, the tumor size was reduced by
3- to 5-fold in pCMVtk-treated animals when gene
delivery was mediated by Tf-lipoplexes as compared with
PBS-treated mice (control) and mice that have received
naked pCMVtk (Po0.001). Figure 2b also shows that
increasing the number of Tf-lipoplex injections did not
improve the therapeutic effect. In fact, a single lipoplex
injection was as effective as two or three injections.
It is important to emphasize that a significant increase
in the survival of the mice treated with Tf-lipoplexes
(carrying the therapeutic gene followed by GCV treatment) was observed when compared with that of controls
(PBS- or GCV-treated animals). In fact, all GCV-treated
mice died before the thirteenth day of treatment, and
only one PBS-treated mouse survived during the whole
treatment. On the other hand, all mice that received
pCMVtk delivered by Tf-lipoplexes followed by GCV
injection survived until the end of the treatment.
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Figure 1 In vivo transfection efficiency of Tf-lipoplexes. SCC-7 cells were injected into the anterior tongue of the syngeneic mice C3H/HeOuJ.
After 5 days, animals with established tumors were injected intratumorally with 50 ml of PBS (control) or lipoplexes prepared from transferrinassociated liposomes composed of DOTAP/Chol complexed with pCMV-SPORT-LacZ (40 mg) at a 3/2 (±) lipid/DNA charge ratio (transfected).
The levels of b-galactosidase gene expression were evaluated by X-gal coloration (a) or immunohistochemistry (b), as described in ‘Materials
and methods’.

Comparison of the antitumoral effect mediated by
HSV-tk/GCV and CD/5-FC therapies
The CD/5-FC suicide gene therapy has been widely reported to be effective in several tumor animal models.34–37
Therefore, we investigated the therapeutic potential
of CD expression mediated by Tf-lipoplexes followed by
5-FC treatment in tumors established in the syngeneic
mice C3H/HeOuJ. The results illustrated in Figure 3 show
that CD gene delivery was also highly effective in
reducing tumor size when mediated by Tf-lipoplexes.
There were no significant differences between the tumor
sizes of CD/5-FC-treated animals and those treated with
HSV-tk/GCV.
Tumor cell apoptosis mediated by HSV-tk/GCV and
CD/5-FC therapies
CD/5-FC and HSV-tk/GCV suicide gene therapy systems
have been reported to induce tumor cell death through
apoptosis in various tumor models.35,38–40 We have shown
previously that human oral cancer cells in culture
transfected with Tf-lipoplexes containing pCMVtk gene
followed by GCV treatment died mainly by an apoptotic
process.27 In the present work, we investigated whether
the tumor regression observed in the HNSCC murine
model upon application of the different treatments was
associated with tumor cell apoptosis. TUNEL staining
has been used extensively to identify cells with nuclear
DNA fragmentation and, therefore, this assay was
selected for these studies. In the animals injected with
PBS, cells were essentially negative for TUNEL staining
(Figure 4). Although a few apoptotic cells could be

detected in the animals injected intratumorally with naked
pCMVtk followed by GCV treatment, or Tf-lipoplexes
carrying pCMVtk but not treated with GCV, the number
of apoptotic cells was very low, indicating the low toxicity
of the lipoplexes. In contrast, a large number of apoptotic
cells were observed in animals injected with Tf-lipoplexes
carrying pCMVtk and treated with GCV. Similar results
were obtained in parallel experiments using CD/5-FC
suicide gene therapy (data not shown).

Tumor infiltration of NK and T cells mediated by
HSV-tk/GCV and CD/5-FC therapies
As T-lymphocytes and natural killer cells (NK cells)
contribute to the antitumoral responses induced by the
immune system,41 we evaluated the tumoral infiltration of
T-lymphocytes (CD3- and CD4-positive cells) and NK
cells following application of the two suicide strategies.
Figure 5 illustrates the results obtained for the extent of
tumoral infiltration of T-lymphocytes and NK cells, as
assessed by immunohistochemistry 8 days after treatment.
An increased infiltration of NK cells, CD3- and CD4-T
cells was observed in tumors from animals injected
with Tf-lipoplexes carrying the suicide genes HSV-tk or
CD and treated with GCV (DOTAP/Chol-Tf-tk) or 5-FC
(data not shown), respectively, compared with intratumoral injection of naked DNA followed by drug
treatment. Tumors from animals injected with control
complexes containing the reporter gene b-galactosidase
(DOTAP/Chol-Tf-b-gal) presented a more extensive cell
infiltration than those from PBS-treated mice (control),
but less extensive than that observed in tumors from
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Figure 3 Comparison of the antitumoral effect mediated by HSV-tk/
GCV and CD/5-fluorocytosine (5-FC) therapies. Five days after
SCC-7 cell implantation, animals with established tumors were
treated with 40 mg of tk or CD genes, naked or complexed with
Tf-liposomes at a 3/2 (±) lipid/DNA charge ratio, and then injected
daily i.p. with 50 mg kg1 GCV or 100 mg kg1 5-FC, respectively.
The tumor size was measured every day. ‘Control’ represents mice
that only received PBS. Results represent the tumor size after
treatment (mean±s.d.) of different experimental groups (n ¼ 10).
Statistical significance between experimental groups and control
group was determined by one-way ANOVA analysis (***Po0.001;
not significant (ns) P40.05).

Figure 2 Antitumoral effect of HSV-tk expression followed by
treatment with GCV in an orthotopic murine model for oral
carcinoma. Induction of the mouse tumor was performed as
described in the legend to Figure 1. (a) Five days after SCC-7 cell
implantation, mice with established tumors were submitted to
intratumoral injection with 40 mg of naked DNA (naked tk) or Tflipoplexes prepared from DOTAP/Chol liposomes at a 3/2 (±) lipid/
DNA charge ratio (DOTAP/Chol-Tf-tk). ‘Control’ represents mice that
only received PBS. DOTAP/Chol-Tf-b-gal represents mice that were
injected with Tf-lipoplexes containing pCMV-SPORT-LacZ and then
treated daily with 50 mg kg1 GCV for 8 days. (b) Mice were further
treated with 40 mg of Tf-lipoplexes, prepared from DOTAP/Chol
liposomes at a 3/2 (±) lipid/DNA charge ratio, at days 2 and 4, and
then injected daily with 50 mg kg1 GCV for 14 days after the first
DNA administration. DOTAP/Chol-Tf-tk 1inj, DOTAP/Chol-Tf-tk 2inj
and DOTAP/Chol-Tf-tk 3inj correspond to mice that received one,
two or three injections of Tf-lipoplexes, respectively. ‘Control’
represents mice that only received PBS, and ‘GCV’ those that only
received GCV treatment. The tumor size was measured every day.
Results represent the tumor size after treatment (mean±s.d.) of
different experimental groups (n ¼ 10). Statistical significance between treated and control groups was determined by one-way
ANOVA analysis (***Po0.001; **Po0.005; not significant (ns)
P40.05).

animals injected with Tf-lipoplexes carrying the suicide
gene. No significant differences were found in the extent
of cell infiltration between control groups (PBS-treated
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mice) and those treated with naked DNA. CD3-T
lymphocytes include both cytotoxic CD8- and helper
CD4-T cells. In the animal groups injected with
Tf-lipoplexes containing the therapeutic or reporter
genes, extensive tumoral infiltration of CD3-T cells was
observed, in contrast with that of CD4-T cells. This result
suggests that the observed tumoral lymphocyte infiltration involves mainly CD8 þ cytotoxic T cells.

Activation of cytokine and chemokine expression
mediated by suicide gene therapy
To further understand the mechanisms involved in
the observed antitumoral effect, we analyzed the tumor
microenvironment by investigating the levels of cytokines and chemokines (IL-2, IL-10, TNF-a, INF-g and
RANTES) using the FlowCytomix assay. Three tumors in
each experimental group (experimental groups involved
injections with Tf-lipoplexes carrying b-galactosidase
(DOTAP/Chol-Tf-b-gal) or HSV-tk followed by treatment with GCV (DOTAP/Chol-Tf-tk) and with naked
tk (naked tk) or PBS (control) were individually analyzed
and the expression levels of each cytokine are presented
in Figure 6. The cytokine IL-2 was overexpressed in
the DOTAP/Chol-Tf-tk group (Po0.05) as compared
with control, naked tk or DOTAP/Chol-Tf-b-gal groups,
which did not exhibit differences in the IL-2 levels. On the
other hand, a reduction of IL-10 expression was observed
in all treated animal groups compared with the control
group (PBS-treated mice), this decrease being more
extensive in the group injected with Tf-lipoplexes carrying
pCMVtk, followed by GCV treatment (data not shown).
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Figure 4 Detection of apoptotic tumor cells in mice treated with HSV-tk/GCV therapy using the TUNEL assay. Induction of the tumor and
treatment were performed as described in the legends to Figures 1 and 2, respectively. Eight days after application of the different treatments,
animals were killed, tumors were removed and 6 mm cryostat sections were obtained. DNA fragmentation as an index of apoptosis was detected
by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL assay). TUNEL-positive nuclei of apoptotic cells were
identified by the presence of dark brown staining. Slices were counterstained with nuclear fast red and observed by light microscopy. Original
magnifications for all panels were  400.

Figure 5 Detection of T-lymphocytes and NK cells in tumors from mice treated with suicide gene therapy. Representative images of tumoral
infiltration of T-lymphocytes and NK cells were obtained by fluorescence microscopy. Induction of the tumor and treatment were performed as
described in the legends to Figures 1 and 2. Eight days after treatment, animals were killed, tumors were removed and 6 mm cryostat sections
were incubated with a rat anti-mouse FITC-labeled mAb against CD3 protein, a rat anti-mouse PE-labeled mAb against CD8 protein and a rat
anti-mouse Alexa Fluor 647-labelled mAb against NK cells. Original magnifications for all panels were  400.

Regarding the INF-g expression, a small but significant
increase was observed in DOTAP/Chol-Tf-tk and DOTAP/
Chol-Tf-b-gal groups (Po0.01) as compared with control
or naked tk groups. Furthermore, intratumoral admini-

stration of Tf-lipoplexes carrying pCMVtk followed by
GCV treatment induced a fourfold increase in the
expression of RANTES (Po0.001) over that observed for
the control or naked tk groups. The levels of TNF-a were
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Figure 6 Detection of cytokines and chemokines in tumors from mice treated with HSV-tk/GCV therapy using the FlowCytomix assay. The
presence of the cytokines IL-2, INF-g and the chemokine RANTES was detected in tumor homogenates by FlowCytomix, an ELISA-based flow
cytometry assay. Induction of tumor and treatment were performed as described in the legends to Figures 1 and 2. Eight days after application of
the different treatments, animals were killed; tumors were removed and homogenized in lysis buffer. Three tumors per condition were analyzed
and the results are expressed as pmol ml1. Statistical significance between treated groups and control groups was determined by one-way
ANOVA analysis (***Po0.001; **Po0.005; *Po0.01; not significant (ns) P40.05).

too low to be detected, independently of the tested
condition.

Discussion

Head and neck cancer is a devastating disease and new
therapeutic modalities are needed. Numerous studies have
been reported regarding the in vivo application of viral
gene therapy for head and neck cancer,42–47 but safety
concerns regarding the use of viral vectors has dampened
the enthusiasm for their use in the clinic. Although viral
vectors are efficient in gene delivery, immune responses
against them are likely to inhibit repeated administrations. Given the limitations and pitfalls of viral gene
therapy, non-viral vectors have been studied as an
alternative for gene delivery in vivo. However, there have
been only a few in vivo applications of non-viral vectors to
deliver therapeutic genes to head and neck tumors, most
likely because of their low transfection activity.48,49
In this work we have demonstrated that Tf-lipoplexes
can mediate transfection of SCC-7 cells in vivo, although
at a relatively low extent (Figure 1). Taking into account
this low transfection efficiency, the significant therapeutic
effect observed (Figures 2 and 3) upon intratumoral
injection of pCMVtk or pCD plasmids in Tf-lipoplexes
followed by GCV or 5-FC treatment, respectively, may be
attributed to the bystander effect. This effect is partly
because of a transfer of the toxic metabolites (phosphorylated GCV and 5-FU), through gap junctions and/or by
phagocytosis of apoptotic vesicles to non-transfected cells,
thereby causing cell death. In this regard, our results
(Figure 4) show that CD/5-FC and HSV-tk/GCV suicide
gene therapy systems induce tumor cell death through
apoptosis, in agreement with other reports.35,38–40
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The bystander effect has been reported to act
differently in various tumor models.17,35 In the murine
model used in the present work both suicide gene therapy
approaches showed the same therapeutic effect in terms of
reducing tumor size. It is interesting to note that in a
prostate tumor model, application of HSV-tk/GCV also
resulted in the same efficiency as that of CD/5-FC
therapy, despite the low levels of connexins and the
consequent poor transfer of the toxic metabolites.50
On the other hand, in a human colorectal tumor mouse
model, the CD/5-FC system proved to be superior to
HSV-tk/GCV therapy, which was explained by the
potential of the CD/5-FC therapy to offer an extracellular
route for the bystander effect, namely the export of 5-FU
(assumed to be freely diffusible as a small, uncharged
molecule) and uptake by neighboring cells in a process
that does not require cell–cell contact.51
The strong therapeutic response promoted by the
bystander effect may also be attributed to the activation
of the immune system. The use of an immunocompetent
murine model, such as that used in the present work,
offers the possibility of studying the contribution of NK
and CD8-T cells and immunomodulators to the tumor
regression induced by the suicide gene therapy.52–55 In this
context, our results show that delivery of the suicide genes
mediated by Tf-lipoplexes results in an increase of
tumoral infiltration of NK and T cells, mainly cytotoxic
CD8-T cells, in the treated animals when compared with
controls (Figure 5). This increase may be partly responsible for the observed antitumoral activity. Nevertheless,
some infiltrations of NK and T cells as well as a slight
increase in the expression of cytokines and chemokines
were also observed in animals treated with Tf-lipoplexes
carrying the reporter gene. This is probably due to the
immunostimulation provoked by cytosine-phosphateguanine (CpG) motifs present in the DNA and by the
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lipoplexes per se. Several studies have demonstrated that
cationic liposome/DNA complexes activate the immune
system. For example, i.p. injection of lipoplexes into
immunocompetent mice resulted in infiltration of inflammatory cells, secretion of INF-g, and increased NK
activity within the peritoneal cavity.56 It has also been
reported that the CpG motifs present in the DNA are
responsible for the immunostimulatory effect, since the
methylation or elimination of these motifs resulted in a
reduction of cytokine production.57–59 These findings may
explain the delay in the tumor growth observed
when mice were injected with Tf-lipoplexes carrying the
b-galactosidase gene (Figure 2a)
The microenvironment of the tumors was also altered
in treated animal groups. A significant increase in IL-2
expression was observed upon intratumoral administration of Tf-lipoplexes carrying the therapeutic gene
following drug treatment (Figure 6). IL-2 is normally
produced during an immune response. The binding of a
tumoral antigen by the T cell receptor can stimulate the
secretion of IL-2 which induces proliferation and differentiation of NK, T and B cells and consequently an
antitumoral effect.60
An increase of the inflammatory cytokine IFN-g and
the chemokine RANTES was also observed in animal
groups injected with Tf-lipoplexes carrying both the
therapeutic and reporter genes. IFN-g is secreted by NK
cells and T-lymphocytes, mainly cytotoxic CD8-T cells.61
Therefore, our observation of an increased expression of
IFN-g likely reflects the tumoral infiltration of these
cells in animals treated with Tf-lipoplexes. Furthermore,
IFN-g is involved in the production of chemokines by a
variety of tumor cells, which act as chemoattractants for
lymphocytes, inhibiting the differentiation and proliferation of endothelial cells and angiogenesis.62,63 Among
these, the inflammatory and chemostatic chemokine
RANTES, with the help of particular cytokines (that is,
IL-2 and IFN-g), has been shown to play an important
role in the recruitment, proliferation and activation of
effector T and NK cells, thus stimulating cytolysis.64
Although the same levels for INF-g and RANTES have
been observed in animal groups injected with Tflipoplexes carrying the therapeutic or reporter genes, the
difference observed in the extent of tumoral infiltration of
NK and T cells, and particularly in tumor regression, for
the two groups may be explained by the selective cell
death induced by the suicide gene therapy. The decreased
expression of IL-10 observed in the animal group treated
with Tf-lipoplexes carrying the therapeutic gene followed
by drug treatment, compared with that found in the other
experimental groups, may also contribute to the observed
difference in tumor size. IL-10 is an immunosuppressive
and anti-inflammatory cytokine which can both inhibit
the synthesis of pro-inflammatory cytokines and suppress
the antigen presentation capacity of antigen-presenting
cells.64,65 Therefore, the decrease in the levels of IL-10
observed in the treated animals may allow increased levels
of IL-2 and infiltration of inflammatory cells, thus
contributing to the pronounced tumor regression in these
animals.

Overall, our results provide evidence that suicide gene
therapy mediated by Tf-lipoplexes induces tumor cell
apoptosis in the syngeneic orthotopic murine model for
head and neck squamous cell carcinoma. Activation of
resident NK and T cells modifies the tumor microenvironment and leads to the recruitment of immune effector
cells that can act as an adjuvant to the suicide gene
strategy. These findings will be important in the future
design of strategies for efficient treatment of human head
and neck squamous cell carcinoma, namely by combining
suicide gene therapy strategies and immunotherapy
through delivery (or co-delivery) of immunomodulator
genes using Tf-lipoplexes.
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